{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:52:17Z","timestamp":1770979937168,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Current data indicate that in the community, approximately 50% of patients with heart failure (HF) have preserved left ventricular (LV) ejection fraction (LVEF)\u2014the so-called HFpEF. Treatment of HFpEF has been considered an unmet need for decades. We believe that the main underlying reasons have been (a) the ever-changing LVEF cut-offs used for HF classification; (b) controversies regarding the definition of the LVEF normal range; (c) the fact that HFpEF does not represent a phenotype, but a category of diseases with entirely different characteristics (hypertensive heart disease, valvular heart disease (VHD), hypertrophic cardiomyopathy (HCM) etc.); (d) the lack of recognition that hypertensive HFpEF is the most common and important HFpEF phenotype; (e) the assumption that neurohormonal overactivity is absent in HF patients with a LVEF &gt; 45\u201350% which has been proven to be wrong. Current HFpEF trials, in which the vast majority of the participants suffered from hypertension (HTN), whereas VHD and HCM were absent, demonstrated that neurohormonal and sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective in HF patients over a wide LVEF range. Thus, restricting these lifesaving treatments to HF patients with reduced LVEF is not justified anymore and it should be additionally considered for HFpEF patients suffering from HTN.<\/jats:p>","DOI":"10.3390\/jcm11133706","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T22:31:14Z","timestamp":1656369074000},"page":"3706","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reshaping Treatment of Heart Failure with Preserved Ejection Fraction"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-067X","authenticated-orcid":false,"given":"Nikolaos","family":"Karamichalakis","sequence":"first","affiliation":[{"name":"6th Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-3946","authenticated-orcid":false,"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4016","authenticated-orcid":false,"given":"Filippos","family":"Triposkiadis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-6411","authenticated-orcid":false,"given":"Ioannis","family":"Paraskevaidis","sequence":"additional","affiliation":[{"name":"6th Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-7564","authenticated-orcid":false,"given":"Elias","family":"Tsougos","sequence":"additional","affiliation":[{"name":"6th Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: Preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research Priorities for Heart Failure with Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"NHFA CSANZ Heart Failure Guidelines Working Group, Atherton, J.J., Sindone, A., De Pasquale, C.G., Driscoll, A., MacDonald, P.S., Hopper, I., Kistler, P.M., Briffa, T., and Wong, J. (2018). National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ., 27, 1123\u20131208.","DOI":"10.1016\/j.hlc.2018.06.1042"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","article-title":"Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week","volume":"77","author":"Lam","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e005652","DOI":"10.1161\/CIRCHEARTFAILURE.118.005652","article-title":"Heart Failure with Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors","volume":"12","author":"Lupon","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_13","first-page":"233","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERP-19-0050","article-title":"Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: A guideline from the British Society of Echocardiography","volume":"7","author":"Harkness","year":"2020","journal-title":"Echo Res. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","article-title":"Routinely reported ejection fraction and mortality in clinical practice: Where does the nadir of risk lie?","volume":"41","author":"Wehner","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ejhf.2047","article-title":"Ejection fraction and mortality: A nationwide register-based cohort study of 499 153 women and men","volume":"23","author":"Stewart","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ehjci\/jez321","article-title":"Increased long-term mortality in women with high left ventricular ejection fraction: Data from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) long-term registry","volume":"21","author":"Gebhard","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone Metabolites in TOPCAT\u2014New Insights into Regional Variation","volume":"376","author":"Desai","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDctcs2100007","article-title":"Behind the Scenes of TOPCAT\u2014Bending to Inform","volume":"1","author":"Pfeffer","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: Moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/ejhf.1837","article-title":"From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum","volume":"22","author":"Triposkiadis","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cjca.2020.12.006","article-title":"Cardiovascular Autonomic Disturbances in Heart Failure with Preserved Ejection Fraction","volume":"37","author":"Badrov","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: Rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: A matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","journal-title":"Postgrad. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2017.03.009","article-title":"Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in \u201cReal-World\u201d Clinical Practice","volume":"69","author":"Desai","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jchf.2018.06.017","article-title":"Heart Failure Outcomes with Volume-Guided Management","volume":"6","author":"Strobeck","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","article-title":"Blood pressure and heart failure","volume":"26","author":"Oh","year":"2020","journal-title":"Clin. Hypertens."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1002\/ehf2.12975","article-title":"Relative contribution of risk factors\/co-morbidities to heart failure pathogenesis: Interaction with ejection fraction","volume":"7","author":"Giamouzis","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/HYPERTENSIONAHA.114.03617","article-title":"Aging, arterial stiffness, and hypertension","volume":"65","author":"Sun","year":"2015","journal-title":"Hypertension"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.1436","article-title":"The role of ventricular-arterial coupling in cardiac disease and heart failure: Assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association","volume":"21","author":"Ikonomidis","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jacc.2007.07.032","article-title":"Impact of arterial load and loading sequence on left ventricular tissue velocities in humans","volume":"50","author":"Borlaug","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.tcm.2018.01.001","article-title":"Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment","volume":"28","author":"Xanthopoulos","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jacc.2019.07.012","article-title":"Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review","volume":"74","author":"Chirinos","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2017.08.029","article-title":"Systolic blood pressure target in systemic arterial hypertension: Is lower ever better? Results from a community-based Caucasian cohort","volume":"48","author":"Cioffi","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10741-021-10103-y","article-title":"Obesity, inflammation, and heart failure: Links and misconceptions","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/jcecho.jcecho_63_17","article-title":"Obesity, Cardiac Remodeling, and Metabolic Profile: Validation of a New Simple Index beyond Body Mass Index","volume":"28","author":"Poli","year":"2018","journal-title":"J. Cardiovasc. Echogr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cardfail.2021.02.015","article-title":"Medical Treatment of Heart Failure: Ignore the Ejection Fraction and Treat All?","volume":"27","author":"Triposkiadis","year":"2021","journal-title":"J. Card. Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/13\/3706\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:07Z","timestamp":1760139547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/13\/3706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":50,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11133706"],"URL":"https:\/\/doi.org\/10.3390\/jcm11133706","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}